Semaglutide, marketed under the brand name Wegovy, is a GLP-1 receptor agonist that works by mimicking the effects of a hormone that targets areas of the brain involved in appetite regulation, helping to reduce hunger and calorie intake. Tirzepatide, branded as Mounjaro, is a dual-action medication that acts on both GLP-1 and GIP receptors, enhancing its effectiveness in promoting weight loss.

Both drugs have shown significant results in clinical trials, with patients experiencing substantial weight loss when combined with lifestyle modifications like diet and exercise. However, potential side effects include nausea, gastrointestinal discomfort, and in rare cases, pancreatitis. These medications should be administered under medical supervision, as they are not suitable for everyone and require careful monitoring to ensure safety and efficacy.